You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 126 No. 8, August 2000 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (24)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Oncology
 •Head & Neck Cancer
 •Neoplasms of Head & Neck
 •Alert me on articles by topic

Antisense Inhibition of Cyclin D1 in Human Head and Neck Squamous Cell Carcinoma

Torahiko Nakashima, MD, PhD; Gary L. Clayman, DDS, MD

Arch Otolaryngol Head Neck Surg. 2000;126:957-961.

Objective  To study the role of cyclin D1 in regulating the biological behavior of head and neck cancer.

Design  Squamous cell carcinoma of the head and neck (SCCHN) cells were stably transfected with an antisense cyclin D1 using lipofectin-mediated transfection. In vitro growth assays, cell cycle analyses, cytotoxicity assays, and in vivo tumorigenicity assays were performed.

Materials  Human SCCHN cell lines TU138, TU167, TU177, TU182, MDA183, and MDA1386 and athymic nude mice were used for this study.

Results  The antisense cyclin D1 transfected cells revealed decreased growth rates in vitro and decreased tumorigenicity in athymic nude mice. Furthermore, antisense cyclin D1 transfection enhanced the chemosensitivity against cisplatin.

Conclusions  These studies provided evidence that overexpression of cyclin D1 may play an important role in growth rates and biological behavior of human head and neck cancer. Additionally, expression of cyclin D1 may make human head and neck cancer cells resistant to platinum-based chemotherapeutic approaches. The ability to suppress the malignant phenotype by down-regulating cyclin D1 expression may provide a new gene therapy approach for patients with head and neck cancer.


From the Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Antisense to Cyclin D1 Inhibits Vascular Endothelial Growth Factor-Stimulated Growth of Vascular Endothelial Cells: Implication of Tumor Vascularization
Yasui et al.
Clin. Cancer Res. 2006;12:4720-4729.
ABSTRACT | FULL TEXT  

Cisplatin-Induced Growth Arrest of Head and Neck Cancer Cells Correlates With Increased Expression of p16 and p53.
Yip et al.
Arch Otolaryngol Head Neck Surg 2006;132:317-326.
ABSTRACT | FULL TEXT  

Constitutive Activation of Signal Transducers and Activators of Transcription 3 Correlates with Cyclin D1 Overexpression and May Provide a Novel Prognostic Marker in Head and Neck Squamous Cell Carcinoma
Masuda et al.
Cancer Res. 2002;62:3351-3355.
ABSTRACT | FULL TEXT  

Cyclin D1 Polymorphism and Expression in Patients with Squamous Cell Carcinoma of the Head and Neck
Holley et al.
Am. J. Pathol. 2001;159:1917-1924.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.